Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC-3: Topical imiquimod for high-grade cervical intraepithelial neoplasia
2016-002096-96Phase 4Active
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2016
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Lesion regression after imiquimod therapy and Adequate treatment of high-grade CIN by LLETZ. Started Sep 2016; status: active.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2016-002096-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002096-96.